Small data, big impact
Why we still need to analyze small datasets in the pharmaceutical world
In the era of "Big Data", do we still need to bother with techniques for analyzing "small data"?
The answer is a resounding "Yes"!
In fact, this is quite common in the pharmaceutical industry. As 2KMM's Adrian Olszewski elaborated in a LinkedIn article, there are several reasons for this:
Ethical reasons
Rarity of a disease
High drop-out rates
Cost and organizational reasons
Statistical reasons
Adrian wrote a lot more detail in his article, and I encourage you to read it fully.